ConductScience.org, home

Paper41565210

Cardiac adverse events associated with dual immune checkpoint inhibitors: a pharmacovigilance analysis from the FDA adverse event reporting system.

Xia H and 7 others. Eur Heart J Cardiovasc Pharmacother, 2026. Cited by 4 papers, by iCite.

Cite this record

ConductScience Library. Cardiac adverse events associated with dual immune checkpoint inhibitors: a pharmacovigilance analysis from the FDA adverse event reporting system. Papers, record 41565210. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41565210

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Cardiac adverse events associated with dual immune checkpoint inhibitors: a pharmacovigilance analysis from the FDA adverse event reporting system.
PubMed
Journal
Eur Heart J Cardiovasc Pharmacother
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
4
iCite
Revised in PubMed
2026-08-13
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Xia HHuanghttps://orcid.org/0000-0001-8217-9742
2Shi LLei
3Luo SShuimei
4Sun ZZequn
5Quan MMengru
6Xiao HHuazhenhttps://orcid.org/0009-0008-1712-1657
7Chen YYu
8Lin JJinghttps://orcid.org/0000-0002-9025-1721

Source PubMed

Download CSV of authors

Topics20

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Immune Checkpoint InhibitorsMajor topic
United States Food and Drug AdministrationMajor topic
Heart DiseasesMajor topic
NeoplasmsMajor topic
Humans
Pharmacovigilance
United States
Adverse Drug Reaction Reporting Systems
Cardiotoxicity
Female
Male
Databases, Factual
Risk Factors
Risk Assessment
Middle Aged
Time Factors
Aged
Treatment Outcome
Retrospective Studies
Adult

Source PubMed

Download CSV of topics

Grants7

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
2023J011254Natural Science Foundation of Fujian ProvincePubMed
2022ZQNZD009Young and Middle-aged Scientific Research Major Project of Fujian Provincial Health CommissionPubMed
2023Y9412Joint Funds for the Innovation of Science and Technology, Fujian provincePubMed
202410392008Fujian Medical University Student Innovation and EntrepreneurshipTraining Project, ChinaPubMed
2023L3020Special Research Funds for Local Science and Technology Development Guided by Central GovernmentPubMed
82350126National Natural Science Foundation of ChinaPubMed
2021QH1278Fujian Medical UniversityPubMed

Source PubMed

Download CSV of grants

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in41849665Cardiotoxicity in dual immune checkpoint inhibitors: a critical appraisal of signal interpretation and future directions.https://conductscience.org/library/papers/41849665

Source PubMed

Download CSV of comments and corrections

References34

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
136600271Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States.J Exp Clin Cancer Res2023https://conductscience.org/library/papers/36600271PubMed
237326100New developments in the mechanism and application of immune checkpoint inhibitors in cancer therapy (Review).Int J Oncol2023https://conductscience.org/library/papers/37326100PubMed
335068882Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated Cardiovascular Toxicities.Acta Cardiol Sin2022https://conductscience.org/library/papers/35068882PubMed
436808819Association between immune checkpoint inhibitors and myocardial infarction in Asians: A population-based self-controlled case series.Cancer Med2023https://conductscience.org/library/papers/36808819PubMed
532257944Treatment-Related Adverse Events of Combination Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis.Front Oncol2020https://conductscience.org/library/papers/32257944PubMed
633643048Cardiotoxicity Induced by Immune Checkpoint Inhibitors: A Pharmacovigilance Study From 2014 to 2019 Based on FAERS.Front Pharmacol2021https://conductscience.org/library/papers/33643048PubMed
728889792Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.N Engl J Med2017https://conductscience.org/library/papers/28889792PubMed
826027431Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.N Engl J Med2015https://conductscience.org/library/papers/26027431PubMed
940884033Incidence and risk factors of immune checkpoint inhibitor myocardial and muscle toxicity: a French nationwide study.Eur Heart J2026https://conductscience.org/library/papers/40884033PubMed
1038375475Immune checkpoint inhibitors associated cardiovascular immune-related adverse events.Front Immunol2024https://conductscience.org/library/papers/38375475PubMed
1131636208Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies.Proc Natl Acad Sci U S A2019https://conductscience.org/library/papers/31636208PubMed
1236017568
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).
Eur Heart J2022https://conductscience.org/library/papers/36017568PubMed
1333937956Cardiotoxicity of Immune Checkpoint Inhibitors.Curr Oncol Rep2021https://conductscience.org/library/papers/33937956PubMed
1437651086Challenges and Opportunities in Accessing and Analysing FAERS Data: A Call Towards a Collaborative Approach.Drug Saf2023https://conductscience.org/library/papers/37651086PubMed
1533705549Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy.J Natl Cancer Inst2021https://conductscience.org/library/papers/33705549PubMed
1639333574Clinical characteristics and influencing factors of anti-PD-1/PD-L1-related severe cardiac adverse event: based on FAERS and TCGA databases.Sci Rep2024https://conductscience.org/library/papers/39333574PubMed
1740569849Immune checkpoint inhibitor-associated myocarditis: a novel risk score.Eur Heart J2026https://conductscience.org/library/papers/40569849PubMed
1838382875Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.Ann Oncol2024https://conductscience.org/library/papers/38382875PubMed
1935277208Cardiotoxicity risk factors with immune checkpoint inhibitors.Cardiooncology2022https://conductscience.org/library/papers/35277208PubMed
2027141885Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination.Nat Rev Clin Oncol2016https://conductscience.org/library/papers/27141885PubMed

See all 34 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.

PMIDTitleJournalYearIn PapersSource
42718552Peripheral blood cells and immune checkpoint inhibitor-associated myocarditis: a retrospective clinical study with pharmacovigilance and single-cell analysis.Front Immunol2026https://conductscience.org/library/papers/42718552PubMed
42591858Immune checkpoint inhibitor-induced cardiotoxicity: from immune mechanisms to clinical surveillance and targeted therapies.Front Cardiovasc Med2026https://conductscience.org/library/papers/42591858PubMed
41849665Cardiotoxicity in dual immune checkpoint inhibitors: a critical appraisal of signal interpretation and future directions.Eur Heart J Cardiovasc Pharmacother2026https://conductscience.org/library/papers/41849665PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41565210

GET https://conductscience.org/api/papers/v1/41565210/references?page=2